Sara A. Hurvitz, MD

Articles

Interesting Trials in HER2+ Breast Cancer

November 1st 2021

Key opinion leaders review data from the phase III TULIP trial in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer and the ExteNET study on extended adjuvant treatment with neratinib.

Updates in HER2+ Breast Cancer from ESMO 2021

October 25th 2021

Expert oncologists discuss data from several phase 2 and phase 3 trials presented at ESMO 2021 on the use of trastuzumab deruxtecan for HER2-positive breast cancer and how it impacts their practices.

Dr. Hurvitz on the Rationale for the coopERA Breast Cancer Trial in ER+/HER2- Breast Cancer

September 29th 2021

Sara A. Hurvitz, MD, discusses the rationale for the phase 2 coopERA Breast Cancer trial in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Hurvitz on Outcomes With Sacituzumab Govitecan in TNBC

September 1st 2021

Sara A. Hurvitz, MD, discusses outcomes with sacituzumab govitecan-hziy in patients with metastatic triple-negative breast cancer.

Dr. Hurvitz on Unmet Needs in HER2+ Breast Cancer

August 12th 2020

Sara A. Hurvitz, MD, discusses unmet needs within the field of HER2-positive breast cancer.

Dr. Hurvitz on the Lack of Predictive Biomarkers in HER2+ Breast Cancer

August 7th 2020

Sara A. Hurvitz, MD, discusses the lack of predictive biomarkers in HER2-positive breast cancer.

Dr. Hurvitz on Reducing Potential Exposure to COVID-19

March 23rd 2020

Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the steps that can be taken to reduce potential exposure to coronavirus disease 2019 (COVID-19).

Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer

March 19th 2020

Sara A. Hurvitz, MD, discusses available treatment options in early-stage HER2-positive breast cancer.

Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer

March 11th 2020

Sara A. Hurvitz, MD, discusses the need for additional research with fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Dr. Hurvitz on the Evolution of Treatment in Metastatic HER2+ Breast Cancer

January 17th 2020

Sara A. Hurvitz, MD, associate professor at the David Geffen School of Medicine, University of California, Los Angeles (UCLA) medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit, co-director of the Santa Monica-UCLA Outpatient Oncology Practices, and director, Breast Cancer Clinical Trials Program, UCLA, discusses the evolution of treatment in metastatic HER2-positive breast cancer.

Dr. Hurvitz on Therapeutics for HER2+ Metastatic Breast Cancer

January 16th 2020

Sara A. Hurvitz, MD, discusses treatment options for patients with HER2-positive metastatic breast cancer.

Dr. Hurvitz on the Findings of DESTINY-Breast01 in HER2+ Metastatic Breast Cancer

January 8th 2020

Sarah A. Hurvitz, MD, medical oncologist, medical director, Clinical Research Unit for University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the findings in the DESTINY-Breast01 trial of patients with HER2-positive metastatic breast cancer.

Dr. Hurvitz on Using ADCs in HER2+ Breast Cancer

December 12th 2019

Sara A. Hurvitz, MD, associate professor of medicine and medical oncologist, University of California Los Angeles, discusses the use of antibody-drug conjugates in HER2-positive breast cancer.

Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast Cancer

March 26th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib in the treatment of patients with HER2-positive breast cancer.

Dr. Hurvitz on Standards of Care in HER2+ Breast Cancer

March 14th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the first- and second-line standards of care in HER2-positive breast cancer.

Dr. Hurvitz on FDA Approval of Subcutaneous Trastuzumab Formulation in HER2+ Breast Cancer

March 9th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the recent FDA approval of subcutaneous use of trastuzumab (Herceptin) and hyaluronidase-oysk injection (Herceptin Hylecta) in the HER2-positive breast cancer space.

Dr. Hurvitz Discusses Role of Pertuzumab in HER2+ Breast Cancer

January 25th 2019

Dr. Hurvitz on Importance of Biosimilars in HER2+ Breast Cancer

December 29th 2018

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the importance of biosimilars in HER2-positive breast cancer.

Dr. Hurvitz on Novel Agents in HER2-Positive Breast Cancer

October 10th 2018

Dr. Hurvitz on HER2-Targeted Therapies in Breast Cancer

September 13th 2018

Sara Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses HER2-targeted therapies for the treatment of breast cancer.